IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
Status:
Recruiting
Trial end date:
2029-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, randomized controlled phase III clinical trial in primary
diagnosed loco-regionally advanced nasopharyngeal carcinoma (NPC) patients. The purpose of
this study is to evaluate the efficacy of induction chemotherapy (IC) combined with low-dose
radiation and immune checkpoint inhibitor (ICI) followed by concurrent chemoradiotherapy
(CCRT) versus IC+CCRT, and compare the treatment-related adverse events and quality of life
in two groups.